Novo Nordisk is in danger of being left behind in haemophilia, and new safety fears around its lead R&D project make this more likely. But could a setback prompt deal…
Another trial seems to suggest that adding VEGF blockade to Parp inhibition does little for patients without tumour mutations.
Despite Astrazeneca stacking the odds in its favour Imfinzi’s Danube trial, in first-line bladder cancer, reads out negatively.
Heightened Beovu safety concerns could turn into a big problem for Novartis, while rival Regeneron will make the most of any uncertainty.
A fresh blow to the beta-amyloid hypothesis has not rattled Biogen's supporters, but Lilly shareholders were apparently hoping for more.
A failed phase III trial has Ipsen clutching at straws to salvage its rare bone disease project palovarotene, which it bought for $1bn a mere 11 months ago.
Amarin must hope that setbacks for Astrazeneca and Acasti show that in Vascepa it has the secret sauce.
The Merck & Co drug’s failure in small-cell lung cancer prompts a theory and leaves the way clear for Roche and Astrazeneca.
The most important clinical readouts of the holiday period concerned Google Health, Axsome, Wave and Spectrum.